Hideaki Ishikawa
Research Subjects
Hideaki Ishikawa has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Ken-Ichiro Otsuyama
From the Department of Bio-Signal Analysis, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
3 shared publicationsMichio M. Kawano
From the Department of Bio-Signal Analysis, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
3 shared publications- Naohiro Tsuyama
Department of Radiation Life Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan
3 shared publications Shangqin Liu
From the Department of Bio-Signal Analysis, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
3 shared publicationsYasuko Maki
From the Department of Bio-Signal Analysis, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
3 shared publicationsZi Ma
From the Department of Bio-Signal Analysis, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
3 shared publications
Latest Publications
- 25 April 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 612, 50-56
Isolation and structural characterization of bioactive glycosaminoglycans from the green-lipped mussel Perna canaliculus
- 25 April 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 612, 50-56
Isolation and structural characterization of bioactive glycosaminoglycans from the green-lipped mussel Perna canaliculus
- Open Access
- 1 November 2020
- Vol. 82 (4) , 775-781
A rare case of myocardial calcification secondary to acute myocarditis due to an Escherichia coli infection
Myocardial calcification secondary to acute myocarditis is a rare but possibly life-threatening complication.
- 1 November 2020
- Vol. 82 (4) , 775-781
Open AccessA rare case of myocardial calcification secondary to acute myocarditis due to an Escherichia coli infection
Myocardial calcification secondary to acute myocarditis is a rare but possibly life-threatening complication.
- 25 February 2014
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 18 (2) , 212-213
“Palliative Hemodialysis” in the Context of End‐of‐Life Care for Dialysis Patients
- 25 February 2014
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 18 (2) , 212-213
“Palliative Hemodialysis” in the Context of End‐of‐Life Care for Dialysis Patients
- Open Access
- 4 December 2013
- Published by Wiley in Case Reports in Nephrology
- Vol. 2013, 1-4
Withdrawal from Dialysis and Palliative Care for Severely Ill Dialysis Patients in terms of Patient-Centered Medicine
We treated a dementia patient with end stage chronic kidney disease (CKD). The patient also had severe chronic heart disease and suffered from untreatable respiratory distress during the clinical course of his illness. We therefore initiated peritoneal dialysis therapy (PD) as renal replacement therapy, although we had difficulties continuing stable PD for many reasons, including a burden on caregivers and complications associated with PD therapy itself. Under these circumstances we considered that palliative care prior to intensive care may have been an optional treatment. This was a distressing decision regarding end-of-life care for this patient. We were unable to confirm the patients preference for end-of-life care due to his dementia. Following sufficiently informed consent the patients family accepted withdrawal from dialysis (WD). We simultaneously initiated nonabandonment and continuation of careful follow-up including palliative care. We concluded that the end-of-life care we provided would contribute to a peaceful and dignified death of the patient. Although intensive care based on assessment of disease is important, there is a limitation to care, and therefore we consider that WD and palliative care are acceptable options for care of our patients in the terminal phase of their lives.
- 4 December 2013
- Published by Wiley in Case Reports in Nephrology
- Vol. 2013, 1-4
Open AccessWithdrawal from Dialysis and Palliative Care for Severely Ill Dialysis Patients in terms of Patient-Centered Medicine
We treated a dementia patient with end stage chronic kidney disease (CKD). The patient also had severe chronic heart disease and suffered from untreatable respiratory distress during the clinical course of his illness. We therefore initiated peritoneal dialysis therapy (PD) as renal replacement therapy, although we had difficulties continuing stable PD for many reasons, including a burden on caregivers and complications associated with PD therapy itself. Under these circumstances we considered that palliative care prior to intensive care may have been an optional treatment. This was a distressing decision regarding end-of-life care for this patient. We were unable to confirm the patients preference for end-of-life care due to his dementia. Following sufficiently informed consent the patients family accepted withdrawal from dialysis (WD). We simultaneously initiated nonabandonment and continuation of careful follow-up including palliative care. We concluded that the end-of-life care we provided would contribute to a peaceful and dignified death of the patient. Although intensive care based on assessment of disease is important, there is a limitation to care, and therefore we consider that WD and palliative care are acceptable options for care of our patients in the terminal phase of their lives.
- 1 August 2008
- Published by IOP Publishing in Japanese Journal of Applied Physics
- Vol. 47 (8R) , 6205
Accurate Determination of the Intrinsic Diffusivities of Boron, Phosphorus, and Arsenic in Silicon: The Influence of SiO2 Films
Accurate determination of the intrinsic diffusivities of boron (B), phosphorus (P), and arsenic (As) in silicon (Si) is reported. We show that the differences in the B, P, and As diffusivities reported in the previous works arise from whether SiO2 films existed on the Si sample surfaces. Impurity diffusion near the Si surface without SiO2 is affected by oxidation of Si even in the nominally inert atmosphere, which has unavoidable residual oxygen background due to the open furnace. On the other hand, a surface SiO2 film of ~20 nm thickness prepared before the diffusion annealing is sufficient to block further oxidation of Si, i.e., truly intrinsic diffusivities of impurities have been obtained from samples having surface oxide layers.
- 1 August 2008
- Published by IOP Publishing in Japanese Journal of Applied Physics
- Vol. 47 (8R) , 6205
Accurate Determination of the Intrinsic Diffusivities of Boron, Phosphorus, and Arsenic in Silicon: The Influence of SiO2 Films
Accurate determination of the intrinsic diffusivities of boron (B), phosphorus (P), and arsenic (As) in silicon (Si) is reported. We show that the differences in the B, P, and As diffusivities reported in the previous works arise from whether SiO2 films existed on the Si sample surfaces. Impurity diffusion near the Si surface without SiO2 is affected by oxidation of Si even in the nominally inert atmosphere, which has unavoidable residual oxygen background due to the open furnace. On the other hand, a surface SiO2 film of ~20 nm thickness prepared before the diffusion annealing is sufficient to block further oxidation of Si, i.e., truly intrinsic diffusivities of impurities have been obtained from samples having surface oxide layers.
- Open Access
- 15 April 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (8) , 3295-3302
A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma
CD45, a receptor-type tyrosine phosphatase, is required for interleukin-6 (IL-6)-induced proliferation in human myeloma cells, which express the shortest isoform, CD45RO, but not the longest isoform, CD45RA. Here, we showed that IL-6 induced the translocation of CD45 to lipid rafts in an isoform-dependent manner. In myeloma cells, CD45RO was translocated to lipid rafts more rapidly than CD45RB, but exogenously expressed CD45RA was not translocated. When an IL-6Rα-transfected B-cell line was stimulated with IL-6, CD45RA was not translocated, although CD45RB was. We further confirmed that the translocated CD45 bound to IL-6Rα, Lyn, and flotillin-2, and this was followed by the dephosphorylation of the negative regulatory Tyr507 of Lyn. CD45 also bound to phosphoprotein associated with glycosphingolipid-enriched microdomains (PAGs), which were subsequently dephosphorylated, resulting in the release of C-terminal src kinase (Csk) from lipid rafts. Therefore, these results indicate that a rapid translocation of CD45RO to lipid rafts may be responsible for IL-6-induced proliferation, and that the change from CD45RA to CD45RO confers the ability to respond to IL-6 in human myeloma cells. (Blood. 2005;105:3295-3302)
- 15 April 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (8) , 3295-3302
Open AccessA rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma
CD45, a receptor-type tyrosine phosphatase, is required for interleukin-6 (IL-6)-induced proliferation in human myeloma cells, which express the shortest isoform, CD45RO, but not the longest isoform, CD45RA. Here, we showed that IL-6 induced the translocation of CD45 to lipid rafts in an isoform-dependent manner. In myeloma cells, CD45RO was translocated to lipid rafts more rapidly than CD45RB, but exogenously expressed CD45RA was not translocated. When an IL-6Rα-transfected B-cell line was stimulated with IL-6, CD45RA was not translocated, although CD45RB was. We further confirmed that the translocated CD45 bound to IL-6Rα, Lyn, and flotillin-2, and this was followed by the dephosphorylation of the negative regulatory Tyr507 of Lyn. CD45 also bound to phosphoprotein associated with glycosphingolipid-enriched microdomains (PAGs), which were subsequently dephosphorylated, resulting in the release of C-terminal src kinase (Csk) from lipid rafts. Therefore, these results indicate that a rapid translocation of CD45RO to lipid rafts may be responsible for IL-6-induced proliferation, and that the change from CD45RA to CD45RO confers the ability to respond to IL-6 in human myeloma cells. (Blood. 2005;105:3295-3302)
- Open Access
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 2458
DHEA Can Inhibit the Proliferation of Myeloma Cells and the IL-6 Production of Bone Marrow Mononuclear Cells from the Myeloma Patients.
Growth expansion of monoclonal plasma cells (myeloma cells) in the bone marrow (BM) is triggered by increase in serum interleukin-6 (IL-6). Indeed, high levels of IL-6 have been found in the serum of patients with progressive multiple myeloma (MM), and a reduction of the tumor cell mass has been reported by inhibition of myeloma cell proliferation with anti-IL-6 antibodies. On the other hand, IL-6 is considered to increase physiologically in its serum level along with age, and the age-related increase in serum IL-6 could be related to the age-dependent diseases such as rheumatoid arthritis, atherosclerosis, Alzheimer’s disease and B cell malignancies including myelomas. Recent reports also show that the age-associated decline in the serum level of an adrenal sex hormone, dehydroepiandrosterone sulfate (DHEA-S), is closely related to the increase in serum IL-6. Here, we show that DHEA-S is decreased significantly more than that by physiological decline with age in overt myeloma, but not in other lymphoid malignancies such as malignant lymphoma or macroglobulinemia. DHEA-S as well as DHEA suppressed IL-6 production from a BM stromal cell line, KM-102, and bone marrow mononuclear cells from patients with MM. Furthermore, DHEA inhibited in vitro growth of the U-266 cell line and primary myeloma cells from the patients, and also in vivo growth of U-266 cells intraperitoneally implanted in SCID-hIL6 transgenic mice. DHEA upregulated the expression of peroxisome proliferator activated receptor (PPAR)β and IκBα gene in myeloma cells and BM stromal cells, which could explain the suppressive effect of DHEA on IL-6 production through the downregulation of NF-κB activity. PPAR agonists such as troglitazone, carbacyclin and WY14643, also inhibited the growth of myeloma cell lines and primary myeloma cells. Therefore, these findings suggest that DHEA has a capability of inhibiting the growth of myeloma cells and IL-6 production of bone marrow mononuclear cells through activation of PPAR and/or suppression of NFκB activity, and inversely a decreased level of DHEA and DHEA-S could upregulate IL-6 activity, which could be responsible for progression of myeloma cells.
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 2458
Open AccessDHEA Can Inhibit the Proliferation of Myeloma Cells and the IL-6 Production of Bone Marrow Mononuclear Cells from the Myeloma Patients.
Growth expansion of monoclonal plasma cells (myeloma cells) in the bone marrow (BM) is triggered by increase in serum interleukin-6 (IL-6). Indeed, high levels of IL-6 have been found in the serum of patients with progressive multiple myeloma (MM), and a reduction of the tumor cell mass has been reported by inhibition of myeloma cell proliferation with anti-IL-6 antibodies. On the other hand, IL-6 is considered to increase physiologically in its serum level along with age, and the age-related increase in serum IL-6 could be related to the age-dependent diseases such as rheumatoid arthritis, atherosclerosis, Alzheimer’s disease and B cell malignancies including myelomas. Recent reports also show that the age-associated decline in the serum level of an adrenal sex hormone, dehydroepiandrosterone sulfate (DHEA-S), is closely related to the increase in serum IL-6. Here, we show that DHEA-S is decreased significantly more than that by physiological decline with age in overt myeloma, but not in other lymphoid malignancies such as malignant lymphoma or macroglobulinemia. DHEA-S as well as DHEA suppressed IL-6 production from a BM stromal cell line, KM-102, and bone marrow mononuclear cells from patients with MM. Furthermore, DHEA inhibited in vitro growth of the U-266 cell line and primary myeloma cells from the patients, and also in vivo growth of U-266 cells intraperitoneally implanted in SCID-hIL6 transgenic mice. DHEA upregulated the expression of peroxisome proliferator activated receptor (PPAR)β and IκBα gene in myeloma cells and BM stromal cells, which could explain the suppressive effect of DHEA on IL-6 production through the downregulation of NF-κB activity. PPAR agonists such as troglitazone, carbacyclin and WY14643, also inhibited the growth of myeloma cell lines and primary myeloma cells. Therefore, these findings suggest that DHEA has a capability of inhibiting the growth of myeloma cells and IL-6 production of bone marrow mononuclear cells through activation of PPAR and/or suppression of NFκB activity, and inversely a decreased level of DHEA and DHEA-S could upregulate IL-6 activity, which could be responsible for progression of myeloma cells.
- Open Access
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 4843
Roles of CD19 Molecules That Suppress Proliferation and Induce Apoptosis in Human Myeloma Cells.
CD19 is a B cell-specific membrane protein belonging to immunoglobulin superfamily, and acts as a positive or negative regulator in B cell signaling. Although plasma cells still express CD19, CD19 expression is lost in malignant plasma cells with the progression of multiple myeloma (MM) including monoclonal gammopathy of undermined significance (MGUS). To understand the pathological significance of loss of CD19 in human myelomas, we examined the biological effect of CD19 expression on myeloma cells by generating CD19 transfectants of a myeloma cell line, U266. CD19 transfectants showed slower growth rate in vitro than controls, such as mock and ΔCD19 transected with a truncated form of CD19. The growth-inhibitory effect was CD19-specific and presumably due to the intracellular signaling events via CD19 because this effect was not observed in ΔCD19. Furthermore, serum withdrawal rapidly induced the apoptosis of the CD19-transfectants that was rescued by insulin-like growth factor (IGF-I) as compared with CD19− controls. These may suggest that the CD19 transfectants are likely to be dependent on the growth factors, such as IGF-I, to survive and proliferate, and thus, susceptible to the serum deprivation-induced apoptosis. IGF-I activates extracellular signal-regulated kinase (ERK) 1/2 and phosphatidylinositol-3-kinase (PI-3K) that are important for proliferation of myeloma cells. Western bolt analysis showed that IGF-1-induced activation of ERK1/2 was reduced in the CD19 transfectants, although the similar levels of IGF-I receptors were expressed in the CD19 transfectants and CD19− controls. In contract, CD19 failed to inhibit the IGF-I-mediated PI-3K/AKT activation, whereas a downstream target in the PI-3K pathway, p70S6 kinase activation was decreased in the CD19 transfectants. However, the p70S6 kinase activity could be influenced by both ERK1/2 and PI-3K pathways after IGF-1 stimulation, and the MAPK pathway seems to be a major regulator for myeloma cell growth. Our results, therefore, suggest that the recovering expression of CD19 molecules and genes in human myeloma cells may be an important consideration in therapeutic approaches in human MM.
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 4843
Open AccessRoles of CD19 Molecules That Suppress Proliferation and Induce Apoptosis in Human Myeloma Cells.
CD19 is a B cell-specific membrane protein belonging to immunoglobulin superfamily, and acts as a positive or negative regulator in B cell signaling. Although plasma cells still express CD19, CD19 expression is lost in malignant plasma cells with the progression of multiple myeloma (MM) including monoclonal gammopathy of undermined significance (MGUS). To understand the pathological significance of loss of CD19 in human myelomas, we examined the biological effect of CD19 expression on myeloma cells by generating CD19 transfectants of a myeloma cell line, U266. CD19 transfectants showed slower growth rate in vitro than controls, such as mock and ΔCD19 transected with a truncated form of CD19. The growth-inhibitory effect was CD19-specific and presumably due to the intracellular signaling events via CD19 because this effect was not observed in ΔCD19. Furthermore, serum withdrawal rapidly induced the apoptosis of the CD19-transfectants that was rescued by insulin-like growth factor (IGF-I) as compared with CD19− controls. These may suggest that the CD19 transfectants are likely to be dependent on the growth factors, such as IGF-I, to survive and proliferate, and thus, susceptible to the serum deprivation-induced apoptosis. IGF-I activates extracellular signal-regulated kinase (ERK) 1/2 and phosphatidylinositol-3-kinase (PI-3K) that are important for proliferation of myeloma cells. Western bolt analysis showed that IGF-1-induced activation of ERK1/2 was reduced in the CD19 transfectants, although the similar levels of IGF-I receptors were expressed in the CD19 transfectants and CD19− controls. In contract, CD19 failed to inhibit the IGF-I-mediated PI-3K/AKT activation, whereas a downstream target in the PI-3K pathway, p70S6 kinase activation was decreased in the CD19 transfectants. However, the p70S6 kinase activity could be influenced by both ERK1/2 and PI-3K pathways after IGF-1 stimulation, and the MAPK pathway seems to be a major regulator for myeloma cell growth. Our results, therefore, suggest that the recovering expression of CD19 molecules and genes in human myeloma cells may be an important consideration in therapeutic approaches in human MM.